Drug or treatment

Golidocitinib clinical trials

• 15Clinical trials
• 4Countries

Newest trials

All recruiting trials (15)

• Golidocitinib and chidamide for cutaneous T-cell lymphoma

  This study tests whether the combo of golidocitinib and chidamide helps people with CTCL that has already received prior systemic therapy.

  Recruiting Phase 1/2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07754890

• MEPL-G combination therapy for NK/T‑cell lymphoma with HLH

  This trial will test whether the MEPL-G drug combination (liposomal mitoxantrone, etoposide, pegaspargase, methylprednisolone, and golidocitinib) can control both the lymphoma and the life‑threatening HLH inflammation in adults with NK/T‑cell lymphoma–associated HLH.

  Recruiting Phase 1/2 Beijing Tongren Hospital · Beijing · NCT07525466

• GW5282 with golidocitinib versus CHOP for peripheral T‑cell lymphoma

  This will test whether combining GW5282 with golidocitinib helps adults with peripheral T‑cell lymphoma more than standard CHOP chemotherapy.

  Recruiting Phase 1/2 Dizal Pharmaceuticals · Chongqing, Chongqing Municipality and 11 other locations · NCT07496229

• Golidocitinib versus placebo as maintenance treatment for PTCL patients in remission after first-line chemotherapy

  This trial tests whether taking golidocitinib every other day can help keep peripheral T‑cell lymphoma from coming back in adults who responded to first‑line chemotherapy but cannot have a stem cell transplant.

  Recruiting Phase 3 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07414758

• Golidocitinib plus selinexor for chronic active Epstein‑Barr virus disease (CAEBVD)

  This trial will try combining golidocitinib and selinexor to treat adults aged 18–70 with chronic active Epstein‑Barr virus disease, including EBV‑associated lymphohistiocytosis.

  Recruiting Phase 2/3 Beijing Friendship Hospital · Beijing · NCT07369739

• Golidocitinib (GO) treatment for hemophagocytic lymphohistiocytosis

  This trial will test whether the oral drug golidocitinib (GO) can safely treat people aged 14–70 with newly diagnosed or relapsed/refractory hemophagocytic lymphohistiocytosis who are not candidates for stem cell transplant.

  Recruiting Phase 2/3 Beijing Friendship Hospital · Beijing, Beijing Municipality · NCT07339345

• Golidocitinib versus placebo as maintenance for peripheral T-cell lymphoma

  This trial will test whether taking golidocitinib every other day can help keep peripheral T‑cell lymphoma in remission for adults who responded to first‑line chemotherapy and are not having a stem cell transplant.

  Recruiting Phase 3 Fudan University · Shanghai · NCT07300514

• Golidocitinib versus physician-selected therapy for relapsed/refractory peripheral T‑cell lymphoma (Phase 3 JACKPOT19)

  This Phase 3 test compares golidocitinib with treatments chosen by a doctor to see if it better controls disease in adults with relapsed or refractory peripheral T‑cell lymphoma.

  Recruiting at 50 sites Phase 3 Dizal Pharmaceuticals · Hefei, Anhui and 50 other locations · NCT07234162

• Golidocitinib plus PD-1 inhibitor maintenance for previously untreated extensive-stage small cell lung cancer

  This trial will see if adding golidocitinib to PD-1 inhibitor maintenance helps people with previously untreated extensive-stage small cell lung cancer.

  Recruiting at 2 sites Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing and 1 other locations · NCT07110103

• Golidocitinib with liposomal mitoxantrone or chidamide for relapsed or refractory peripheral T‑cell lymphoma

  This trial tests whether adding golidocitinib to either liposomal mitoxantrone or chidamide helps adults with relapsed or refractory peripheral T‑cell lymphoma.

  Recruiting Phase 1/2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07093710

• Golidocitinib plus tislelizumab and chemotherapy for first-line advanced NSCLC

  This phase 1 trial will try adding golidocitinib to tislelizumab and chemotherapy to see if people with advanced NSCLC and PD-L1 ≥1% can live longer without their cancer getting worse.

  Recruiting Phase 1 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT06969612

• Evaluating a new treatment for relapsed or refractory NK/T-cell lymphoma

  This study is testing a new combination treatment for people with relapsed or hard-to-treat NK/T-cell lymphoma to see if it can help them when other treatments haven't worked.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shangai · NCT06966154

• Combining Golidocitinib and Pomalidomide for treating relapsed T-cell lymphoma

  This study is testing a new combination of two medications, Golidocitinib and Pomalidomide, to see if it can help people with relapsed T-cell lymphoma feel better.

  Recruiting Phase 1/2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06855823

• Combination treatment for relapsed or refractory natural killer T-cell lymphoma

  This study is testing a new combination of two medications to see if they can help people with a type of lymphoma that hasn't responded to previous treatments.

  Recruiting at 2 sites Phase 2 Sun Yat-sen University · Beijing, Beijing Municipality and 1 other locations · NCT06733051

• Evaluating Golidocitinib for Newly Diagnosed Peripheral T Cell Lymphoma

  This study is testing a new drug called golidocitinib to see if it can help people with newly diagnosed peripheral T cell lymphoma live longer without their cancer getting worse.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06630091

Quick answers

How many clinical trials of Golidocitinib are recruiting right now?

15, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 4 countries. The most sites are in China (14 trials), Taiwan (1 trial), Thailand (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 6, Phase 3: 3, Phase 2: 3, Phase 2/3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →